Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edema Arm Clear all
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

NCT05569148
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Faricimab PFS Configuration
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Mesa, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 22, 2026, 9:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Aflibercept 8 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 4 Interventional

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144
View directory record Official record
Conditions
Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Interventions
Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Results available

Lymphedema Study for Arm or Leg Lymphedema

NCT02257970
View directory record Official record
Conditions
Lymphedema
Interventions
Ketoprofen, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

NCT04516278
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Beverly Hills, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study

NCT01247220
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

NCT05512962
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter
Drug · Device
Lead sponsor
Oxular Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Bakersfield, California • Minneapolis, Minnesota • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 9:19 AM EDT
Active, not recruiting No phase listed Observational

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Pneumatic Tourniquet on Arm Swelling After Lymph Node Removal

NCT03584100
View directory record Official record
Conditions
Healthy Subject
Interventions
Tourniquet 8000
Device
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 22, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional

Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)

NCT05695924
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Device · Procedure
Lead sponsor
Fibralign Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 22, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

NCT04606030
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Device · Procedure
Lead sponsor
Fibralign Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 22, 2026, 9:19 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
View directory record Official record
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Jul 22, 2026, 9:19 AM EDT
Active, not recruiting No phase listed Observational

Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

NCT04608149
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload
Interventions
Carpediem System
Device
Lead sponsor
Mozarc Medical US LLC
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, Minnesota • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 9:19 AM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 22, 2026, 9:19 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 9:19 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 22, 2026, 9:19 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 22, 2026, 9:19 AM EDT
Completed Not applicable Interventional

Pain, Range of Motion, Edema, Sensibility, Strength (PRESS) & Self-reported Function Create a Comprehensive Score

NCT06155617
View directory record Official record
Conditions
Hand Injuries and Disorders, Upper Extremity Problem
Interventions
Upper Extremity Rehabilitation
Other
Lead sponsor
Howard University
Other
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 22, 2026, 9:19 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 22, 2026, 9:19 AM EDT